Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Health Maintenance Organizations | 23 | 2013 | 658 | 1.090 |
Why?
|
Databases, Factual | 23 | 2024 | 7963 | 1.050 |
Why?
|
Drug Prescriptions | 12 | 2019 | 1669 | 1.000 |
Why?
|
Drug Utilization | 10 | 2018 | 1186 | 0.880 |
Why?
|
Stillbirth | 2 | 2022 | 368 | 0.760 |
Why?
|
Drug Therapy | 7 | 2019 | 503 | 0.750 |
Why?
|
International Classification of Diseases | 7 | 2021 | 912 | 0.720 |
Why?
|
Pregnancy in Diabetics | 1 | 2019 | 197 | 0.600 |
Why?
|
Pregnancy Complications | 6 | 2018 | 2948 | 0.600 |
Why?
|
Pregnancy | 32 | 2024 | 29869 | 0.590 |
Why?
|
Birth Certificates | 4 | 2013 | 71 | 0.560 |
Why?
|
Patient Compliance | 8 | 2018 | 2688 | 0.520 |
Why?
|
Pregnancy Outcome | 7 | 2024 | 2921 | 0.520 |
Why?
|
Abnormalities, Drug-Induced | 4 | 2015 | 339 | 0.500 |
Why?
|
Prenatal Care | 5 | 2016 | 1140 | 0.480 |
Why?
|
Drug Utilization Review | 4 | 2018 | 248 | 0.480 |
Why?
|
Validation Studies as Topic | 2 | 2012 | 162 | 0.480 |
Why?
|
Hypoglycemic Agents | 6 | 2019 | 3085 | 0.440 |
Why?
|
Diabetes, Gestational | 3 | 2019 | 1250 | 0.440 |
Why?
|
Live Birth | 4 | 2022 | 510 | 0.410 |
Why?
|
Pharmacoepidemiology | 4 | 2013 | 350 | 0.410 |
Why?
|
Prescriptions | 2 | 2023 | 386 | 0.400 |
Why?
|
Depressive Disorder | 3 | 2016 | 3735 | 0.380 |
Why?
|
Antidepressive Agents | 5 | 2015 | 2896 | 0.350 |
Why?
|
Hypolipidemic Agents | 4 | 2008 | 609 | 0.350 |
Why?
|
Drug Labeling | 5 | 2014 | 248 | 0.340 |
Why?
|
Diabetes Mellitus | 6 | 2019 | 5838 | 0.330 |
Why?
|
Prenatal Exposure Delayed Effects | 5 | 2019 | 2518 | 0.330 |
Why?
|
Teratogens | 2 | 2008 | 117 | 0.330 |
Why?
|
Antipsychotic Agents | 2 | 2013 | 3067 | 0.320 |
Why?
|
Prescription Drugs | 1 | 2016 | 631 | 0.310 |
Why?
|
Algorithms | 11 | 2021 | 14024 | 0.310 |
Why?
|
Persistent Fetal Circulation Syndrome | 1 | 2009 | 80 | 0.310 |
Why?
|
Estrogen Replacement Therapy | 5 | 2008 | 1208 | 0.300 |
Why?
|
Pregnancy Trimesters | 3 | 2018 | 197 | 0.290 |
Why?
|
Adverse Drug Reaction Reporting Systems | 5 | 2018 | 494 | 0.290 |
Why?
|
Medical Records Systems, Computerized | 5 | 2013 | 1191 | 0.280 |
Why?
|
Pharmaceutical Preparations | 3 | 2012 | 1086 | 0.280 |
Why?
|
Diphosphonates | 3 | 2010 | 635 | 0.280 |
Why?
|
Insurance, Health | 2 | 2012 | 2495 | 0.270 |
Why?
|
Ischemic Attack, Transient | 1 | 2012 | 874 | 0.260 |
Why?
|
United States | 42 | 2024 | 72292 | 0.260 |
Why?
|
Insurance, Pharmaceutical Services | 4 | 2010 | 348 | 0.240 |
Why?
|
Cardiovascular Agents | 2 | 2008 | 840 | 0.230 |
Why?
|
Gestational Age | 3 | 2022 | 3577 | 0.220 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 2008 | 512 | 0.220 |
Why?
|
Pregnancy Trimester, First | 2 | 2019 | 908 | 0.210 |
Why?
|
Consumer Product Safety | 2 | 2014 | 122 | 0.210 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2014 | 3245 | 0.210 |
Why?
|
Retrospective Studies | 35 | 2023 | 80583 | 0.210 |
Why?
|
Female | 74 | 2024 | 392203 | 0.200 |
Why?
|
Medical Record Linkage | 3 | 2013 | 286 | 0.200 |
Why?
|
Hospital Information Systems | 1 | 2005 | 394 | 0.200 |
Why?
|
Therapeutics | 1 | 2002 | 113 | 0.200 |
Why?
|
Research Design | 5 | 2019 | 6174 | 0.200 |
Why?
|
Calcitonin | 1 | 2003 | 329 | 0.200 |
Why?
|
Prevalence | 11 | 2016 | 15702 | 0.200 |
Why?
|
Registries | 5 | 2018 | 8209 | 0.200 |
Why?
|
Fees, Pharmaceutical | 1 | 2002 | 66 | 0.200 |
Why?
|
Radiculopathy | 1 | 2023 | 201 | 0.190 |
Why?
|
Rhabdomyolysis | 4 | 2007 | 152 | 0.190 |
Why?
|
Population Surveillance | 5 | 2014 | 2597 | 0.190 |
Why?
|
Churg-Strauss Syndrome | 3 | 2007 | 75 | 0.190 |
Why?
|
Rheumatic Diseases | 1 | 2008 | 649 | 0.180 |
Why?
|
Medication Adherence | 5 | 2010 | 2175 | 0.180 |
Why?
|
Drug Monitoring | 5 | 2007 | 960 | 0.180 |
Why?
|
Endpoint Determination | 2 | 2014 | 590 | 0.180 |
Why?
|
Peptic Ulcer | 1 | 2002 | 217 | 0.180 |
Why?
|
Muscular Diseases | 1 | 2005 | 552 | 0.180 |
Why?
|
Infant, Newborn | 14 | 2016 | 26183 | 0.170 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2003 | 396 | 0.170 |
Why?
|
Product Surveillance, Postmarketing | 4 | 2024 | 452 | 0.170 |
Why?
|
Medical Records | 4 | 2014 | 1408 | 0.170 |
Why?
|
Middle Aged | 50 | 2023 | 220603 | 0.170 |
Why?
|
Adult | 42 | 2023 | 220995 | 0.170 |
Why?
|
Adolescent | 26 | 2019 | 88247 | 0.170 |
Why?
|
Young Adult | 18 | 2023 | 59191 | 0.170 |
Why?
|
Humans | 89 | 2024 | 760740 | 0.170 |
Why?
|
Predictive Value of Tests | 11 | 2013 | 15250 | 0.170 |
Why?
|
Insurance Claim Review | 5 | 2012 | 741 | 0.160 |
Why?
|
Sentinel Surveillance | 2 | 2024 | 291 | 0.160 |
Why?
|
Risk Management | 1 | 2002 | 557 | 0.160 |
Why?
|
Glyburide | 1 | 2019 | 116 | 0.160 |
Why?
|
Government Regulation | 2 | 2014 | 524 | 0.160 |
Why?
|
Gout | 4 | 2010 | 621 | 0.150 |
Why?
|
Antihypertensive Agents | 1 | 2008 | 2018 | 0.150 |
Why?
|
Antirheumatic Agents | 1 | 2008 | 1365 | 0.150 |
Why?
|
Cohort Studies | 22 | 2023 | 41464 | 0.150 |
Why?
|
Fertilization | 1 | 2019 | 198 | 0.150 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2002 | 1116 | 0.150 |
Why?
|
Gout Suppressants | 2 | 2010 | 177 | 0.150 |
Why?
|
Morning Sickness | 1 | 2017 | 6 | 0.140 |
Why?
|
Fractures, Bone | 3 | 2010 | 2045 | 0.140 |
Why?
|
Biomedical Research | 1 | 2012 | 3426 | 0.140 |
Why?
|
Drug Approval | 2 | 2014 | 812 | 0.130 |
Why?
|
Ondansetron | 1 | 2017 | 95 | 0.130 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2018 | 258 | 0.130 |
Why?
|
Trimethoprim | 1 | 2015 | 78 | 0.130 |
Why?
|
Maternal Age | 2 | 2016 | 809 | 0.130 |
Why?
|
United States Food and Drug Administration | 4 | 2016 | 1661 | 0.130 |
Why?
|
Antiemetics | 1 | 2017 | 186 | 0.120 |
Why?
|
Hip Fractures | 1 | 2003 | 988 | 0.120 |
Why?
|
Estrogens | 3 | 2008 | 1521 | 0.120 |
Why?
|
Aromatase Inhibitors | 1 | 2019 | 513 | 0.120 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 2 | 2008 | 431 | 0.120 |
Why?
|
Progestins | 2 | 2008 | 301 | 0.120 |
Why?
|
Buprenorphine | 1 | 2022 | 656 | 0.120 |
Why?
|
Schizophrenia | 1 | 2013 | 6929 | 0.110 |
Why?
|
Outpatients | 3 | 2023 | 1596 | 0.110 |
Why?
|
Ambulatory Care | 5 | 2007 | 2768 | 0.110 |
Why?
|
Medical Futility | 1 | 2014 | 136 | 0.110 |
Why?
|
Labor, Induced | 1 | 2014 | 151 | 0.110 |
Why?
|
Pregnancy Trimester, Third | 3 | 2013 | 582 | 0.110 |
Why?
|
Analgesics, Opioid | 3 | 2023 | 3805 | 0.110 |
Why?
|
Potassium | 2 | 2007 | 1311 | 0.100 |
Why?
|
Delivery, Obstetric | 2 | 2013 | 939 | 0.100 |
Why?
|
Homes for the Aged | 1 | 2014 | 273 | 0.100 |
Why?
|
Women's Health | 3 | 2014 | 2066 | 0.100 |
Why?
|
Bone Density Conservation Agents | 2 | 2010 | 794 | 0.100 |
Why?
|
Drug Substitution | 1 | 2014 | 290 | 0.100 |
Why?
|
Aged | 35 | 2023 | 169092 | 0.100 |
Why?
|
Data Mining | 2 | 2013 | 551 | 0.090 |
Why?
|
Creatinine | 2 | 2007 | 1895 | 0.090 |
Why?
|
Anti-Asthmatic Agents | 2 | 2007 | 574 | 0.090 |
Why?
|
Stroke | 3 | 2012 | 9715 | 0.090 |
Why?
|
Data Collection | 2 | 2012 | 3316 | 0.090 |
Why?
|
Perinatal Care | 1 | 2013 | 244 | 0.090 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2008 | 1517 | 0.090 |
Why?
|
Medication Errors | 2 | 2005 | 783 | 0.080 |
Why?
|
Quality of Health Care | 1 | 2004 | 4325 | 0.080 |
Why?
|
Epidemiology | 1 | 2011 | 279 | 0.080 |
Why?
|
Infant | 6 | 2021 | 36157 | 0.080 |
Why?
|
Progesterone Congeners | 2 | 2005 | 44 | 0.080 |
Why?
|
Antifungal Agents | 1 | 2013 | 753 | 0.070 |
Why?
|
Sulfonamides | 2 | 2015 | 1977 | 0.070 |
Why?
|
Hyperkalemia | 2 | 2007 | 233 | 0.070 |
Why?
|
Monitoring, Physiologic | 2 | 2006 | 1780 | 0.070 |
Why?
|
Gemfibrozil | 1 | 2007 | 30 | 0.070 |
Why?
|
Opioid-Related Disorders | 1 | 2022 | 2164 | 0.070 |
Why?
|
Calcium Channel Blockers | 1 | 2010 | 694 | 0.070 |
Why?
|
Pharmacies | 2 | 2006 | 167 | 0.070 |
Why?
|
Male | 37 | 2023 | 360402 | 0.070 |
Why?
|
Health Care Surveys | 2 | 2013 | 2422 | 0.070 |
Why?
|
Risk Assessment | 7 | 2015 | 23974 | 0.070 |
Why?
|
Practice Guidelines as Topic | 1 | 2004 | 7390 | 0.070 |
Why?
|
Random Allocation | 1 | 2011 | 2392 | 0.070 |
Why?
|
Nursing Homes | 1 | 2014 | 1083 | 0.070 |
Why?
|
Maternal-Fetal Exchange | 1 | 2009 | 461 | 0.070 |
Why?
|
Fenofibrate | 1 | 2007 | 87 | 0.070 |
Why?
|
Polypharmacy | 2 | 2006 | 306 | 0.070 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2014 | 1351 | 0.070 |
Why?
|
Specialization | 1 | 2011 | 778 | 0.070 |
Why?
|
Hypertension | 3 | 2008 | 8532 | 0.070 |
Why?
|
Bone Resorption | 1 | 2010 | 723 | 0.070 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2009 | 385 | 0.060 |
Why?
|
Child | 9 | 2019 | 80089 | 0.060 |
Why?
|
Correspondence as Topic | 1 | 2005 | 34 | 0.060 |
Why?
|
Gynecology | 1 | 2011 | 526 | 0.060 |
Why?
|
Clofibric Acid | 1 | 2004 | 8 | 0.060 |
Why?
|
Cooperative Behavior | 1 | 2012 | 1505 | 0.060 |
Why?
|
Insulin | 1 | 2019 | 6593 | 0.060 |
Why?
|
Sensitivity and Specificity | 5 | 2013 | 14649 | 0.060 |
Why?
|
Osteoporosis | 3 | 2010 | 1604 | 0.060 |
Why?
|
Amiodarone | 1 | 2006 | 217 | 0.060 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2010 | 1241 | 0.060 |
Why?
|
Aged, 80 and over | 15 | 2015 | 58919 | 0.060 |
Why?
|
Obstetrics | 1 | 2011 | 666 | 0.060 |
Why?
|
Prescription Fees | 1 | 2005 | 153 | 0.060 |
Why?
|
Self Administration | 1 | 2005 | 387 | 0.060 |
Why?
|
Hyperglycemia | 1 | 2013 | 1375 | 0.060 |
Why?
|
Drugs, Generic | 1 | 2009 | 448 | 0.060 |
Why?
|
Macrolides | 1 | 2004 | 204 | 0.050 |
Why?
|
Evaluation Studies as Topic | 1 | 2005 | 1624 | 0.050 |
Why?
|
Hypoglycemia | 1 | 2010 | 883 | 0.050 |
Why?
|
Spironolactone | 1 | 2007 | 409 | 0.050 |
Why?
|
Insurance Coverage | 1 | 2014 | 1937 | 0.050 |
Why?
|
Central Nervous System Stimulants | 1 | 2011 | 1177 | 0.050 |
Why?
|
Sulfonylurea Compounds | 1 | 2004 | 219 | 0.050 |
Why?
|
Anticonvulsants | 1 | 2012 | 1910 | 0.050 |
Why?
|
Irritable Bowel Syndrome | 1 | 2008 | 452 | 0.050 |
Why?
|
Socioeconomic Factors | 2 | 2013 | 7805 | 0.050 |
Why?
|
Health Services Research | 2 | 2013 | 1808 | 0.050 |
Why?
|
Duodenal Ulcer | 1 | 2002 | 121 | 0.050 |
Why?
|
Stomach Ulcer | 1 | 2002 | 122 | 0.050 |
Why?
|
Metformin | 2 | 2013 | 906 | 0.050 |
Why?
|
Delivery of Health Care | 2 | 2015 | 5334 | 0.050 |
Why?
|
Cost Sharing | 1 | 2005 | 409 | 0.050 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2014 | 2149 | 0.050 |
Why?
|
Duodenal Diseases | 1 | 2002 | 99 | 0.050 |
Why?
|
Liver Function Tests | 1 | 2003 | 524 | 0.050 |
Why?
|
Drug Administration Schedule | 4 | 2010 | 4845 | 0.050 |
Why?
|
Antiviral Agents | 1 | 2014 | 3037 | 0.050 |
Why?
|
Wrist Injuries | 1 | 2003 | 214 | 0.050 |
Why?
|
Drug Design | 1 | 2006 | 1045 | 0.050 |
Why?
|
Diabetes Mellitus, Type 2 | 4 | 2011 | 12143 | 0.050 |
Why?
|
Alendronate | 1 | 2002 | 175 | 0.050 |
Why?
|
Electronics | 1 | 2022 | 317 | 0.040 |
Why?
|
Guideline Adherence | 3 | 2006 | 2218 | 0.040 |
Why?
|
Intestinal Perforation | 1 | 2002 | 249 | 0.040 |
Why?
|
Fetus | 1 | 2007 | 1862 | 0.040 |
Why?
|
Dementia | 1 | 2014 | 2686 | 0.040 |
Why?
|
Back Pain | 1 | 2023 | 545 | 0.040 |
Why?
|
Thyroid Gland | 1 | 2006 | 1170 | 0.040 |
Why?
|
Health Services | 1 | 2005 | 751 | 0.040 |
Why?
|
Databases as Topic | 3 | 2007 | 473 | 0.040 |
Why?
|
Epilepsy | 2 | 2012 | 3303 | 0.040 |
Why?
|
Hospitalization | 4 | 2004 | 10708 | 0.040 |
Why?
|
Sex Distribution | 3 | 2015 | 2278 | 0.040 |
Why?
|
Insulin Resistance | 1 | 2013 | 3954 | 0.040 |
Why?
|
Cardiovascular Diseases | 4 | 2011 | 15498 | 0.040 |
Why?
|
Competitive Medical Plans | 2 | 2009 | 26 | 0.040 |
Why?
|
Chi-Square Distribution | 3 | 2013 | 3410 | 0.040 |
Why?
|
Age Distribution | 3 | 2015 | 2872 | 0.040 |
Why?
|
Insemination, Artificial | 1 | 2019 | 99 | 0.040 |
Why?
|
Opiate Substitution Treatment | 1 | 2022 | 444 | 0.040 |
Why?
|
Allopurinol | 2 | 2010 | 198 | 0.040 |
Why?
|
Seizures | 1 | 2010 | 2964 | 0.040 |
Why?
|
Benzodiazepines | 1 | 2023 | 1133 | 0.040 |
Why?
|
Risk | 4 | 2012 | 9603 | 0.040 |
Why?
|
Cognition | 1 | 2015 | 6988 | 0.040 |
Why?
|
Asthma | 2 | 2007 | 6234 | 0.040 |
Why?
|
Reproducibility of Results | 2 | 2015 | 20077 | 0.040 |
Why?
|
Fertility | 1 | 2022 | 769 | 0.040 |
Why?
|
Comorbidity | 5 | 2014 | 10507 | 0.030 |
Why?
|
Spinal Fractures | 1 | 2003 | 704 | 0.030 |
Why?
|
Models, Statistical | 1 | 2011 | 5074 | 0.030 |
Why?
|
Managed Care Programs | 3 | 2008 | 937 | 0.030 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2011 | 3708 | 0.030 |
Why?
|
Age Factors | 6 | 2010 | 18381 | 0.030 |
Why?
|
Electronic Health Records | 3 | 2024 | 4810 | 0.030 |
Why?
|
Risk Factors | 8 | 2015 | 74128 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 2006 | 3705 | 0.030 |
Why?
|
Anti-Bacterial Agents | 3 | 2015 | 7403 | 0.030 |
Why?
|
Postmenopause | 1 | 2005 | 2511 | 0.030 |
Why?
|
Headache | 1 | 2023 | 1255 | 0.030 |
Why?
|
Chronic Disease | 3 | 2010 | 9310 | 0.030 |
Why?
|
Data Interpretation, Statistical | 1 | 2005 | 2689 | 0.030 |
Why?
|
Child, Preschool | 4 | 2011 | 42193 | 0.030 |
Why?
|
Osteoarthritis | 1 | 2002 | 1063 | 0.030 |
Why?
|
Odds Ratio | 3 | 2014 | 9644 | 0.030 |
Why?
|
Mental Status Schedule | 1 | 2014 | 315 | 0.030 |
Why?
|
Patient Acceptance of Health Care | 1 | 2008 | 3196 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2008 | 4010 | 0.030 |
Why?
|
Incidence | 4 | 2018 | 21339 | 0.030 |
Why?
|
Drug Costs | 1 | 2002 | 1183 | 0.030 |
Why?
|
Disease Management | 1 | 2004 | 2506 | 0.030 |
Why?
|
Genital Neoplasms, Female | 1 | 2018 | 532 | 0.030 |
Why?
|
Uric Acid | 2 | 2010 | 806 | 0.030 |
Why?
|
Alzheimer Disease | 1 | 2014 | 8603 | 0.030 |
Why?
|
Confidence Intervals | 2 | 2009 | 2925 | 0.030 |
Why?
|
New England | 2 | 2006 | 1050 | 0.030 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2007 | 2423 | 0.030 |
Why?
|
Obstetric Labor Complications | 1 | 2014 | 236 | 0.020 |
Why?
|
Sex Factors | 4 | 2010 | 10549 | 0.020 |
Why?
|
Pregnancy, Multiple | 1 | 2013 | 215 | 0.020 |
Why?
|
Drug Therapy, Combination | 3 | 2007 | 6305 | 0.020 |
Why?
|
Time Factors | 5 | 2014 | 39908 | 0.020 |
Why?
|
Postpartum Period | 1 | 2018 | 1178 | 0.020 |
Why?
|
Fertilization in Vitro | 1 | 2019 | 1292 | 0.020 |
Why?
|
Liver | 1 | 2006 | 7512 | 0.020 |
Why?
|
Clinical Laboratory Techniques | 2 | 2006 | 745 | 0.020 |
Why?
|
Administration, Oral | 2 | 2010 | 4010 | 0.020 |
Why?
|
Pregnancy Trimester, Second | 1 | 2013 | 730 | 0.020 |
Why?
|
Likelihood Functions | 1 | 2013 | 991 | 0.020 |
Why?
|
Sulfinpyrazone | 1 | 2009 | 15 | 0.020 |
Why?
|
Neoplasms | 1 | 2018 | 22131 | 0.020 |
Why?
|
Probenecid | 1 | 2009 | 73 | 0.020 |
Why?
|
Obesity | 1 | 2011 | 12934 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2014 | 1700 | 0.020 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2013 | 376 | 0.020 |
Why?
|
Colchicine | 1 | 2010 | 259 | 0.020 |
Why?
|
Drug Administration Routes | 1 | 2008 | 150 | 0.020 |
Why?
|
Hospice Care | 1 | 2014 | 677 | 0.020 |
Why?
|
Reference Values | 1 | 2015 | 4919 | 0.020 |
Why?
|
Heart Failure | 1 | 2012 | 11670 | 0.020 |
Why?
|
Naproxen | 1 | 2007 | 100 | 0.020 |
Why?
|
Cross-Sectional Studies | 4 | 2015 | 26065 | 0.020 |
Why?
|
Geriatric Assessment | 1 | 2015 | 1411 | 0.020 |
Why?
|
Logistic Models | 3 | 2009 | 13248 | 0.020 |
Why?
|
Infertility, Female | 1 | 2013 | 760 | 0.020 |
Why?
|
Leukotriene Antagonists | 1 | 2007 | 124 | 0.020 |
Why?
|
Hematologic Neoplasms | 1 | 2018 | 1896 | 0.020 |
Why?
|
Breast Neoplasms | 3 | 2018 | 20988 | 0.020 |
Why?
|
Pharmacology, Clinical | 1 | 2006 | 22 | 0.020 |
Why?
|
Obstetric Labor, Premature | 1 | 2007 | 272 | 0.020 |
Why?
|
Insurance Claim Reporting | 1 | 2006 | 165 | 0.020 |
Why?
|
Antidepressive Agents, Tricyclic | 1 | 2007 | 432 | 0.020 |
Why?
|
Lactones | 1 | 2007 | 316 | 0.020 |
Why?
|
Observation | 1 | 2007 | 310 | 0.020 |
Why?
|
Thyroid Neoplasms | 1 | 2018 | 2332 | 0.020 |
Why?
|
Sulfones | 1 | 2007 | 447 | 0.020 |
Why?
|
Episode of Care | 1 | 2005 | 127 | 0.020 |
Why?
|
Medical Audit | 1 | 2006 | 453 | 0.010 |
Why?
|
Community Pharmacy Services | 1 | 2004 | 52 | 0.010 |
Why?
|
Probability | 1 | 2010 | 2475 | 0.010 |
Why?
|
Program Evaluation | 1 | 2012 | 2486 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2023 | 7873 | 0.010 |
Why?
|
Multivariate Analysis | 2 | 2009 | 12043 | 0.010 |
Why?
|
Pilot Projects | 1 | 2017 | 8619 | 0.010 |
Why?
|
Medicare | 1 | 2002 | 6774 | 0.010 |
Why?
|
Death, Sudden, Cardiac | 1 | 2011 | 1551 | 0.010 |
Why?
|
Treatment Outcome | 5 | 2010 | 64572 | 0.010 |
Why?
|
Financing, Personal | 1 | 2005 | 308 | 0.010 |
Why?
|
Hypothyroidism | 1 | 2008 | 668 | 0.010 |
Why?
|
Proportional Hazards Models | 2 | 2010 | 12448 | 0.010 |
Why?
|
Treatment Refusal | 1 | 2004 | 429 | 0.010 |
Why?
|
Hypercholesterolemia | 1 | 2008 | 1141 | 0.010 |
Why?
|
Follow-Up Studies | 2 | 2015 | 39062 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2010 | 2160 | 0.010 |
Why?
|
Melanoma | 1 | 2018 | 5696 | 0.010 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 2270 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 2007 | 1265 | 0.010 |
Why?
|
Quality Improvement | 1 | 2014 | 3801 | 0.010 |
Why?
|
Case-Control Studies | 2 | 2007 | 22153 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2010 | 6473 | 0.010 |
Why?
|
Drug Industry | 1 | 2005 | 788 | 0.010 |
Why?
|
Myocardial Infarction | 2 | 2011 | 11458 | 0.010 |
Why?
|
Epidemiologic Research Design | 1 | 2002 | 368 | 0.010 |
Why?
|
Severity of Illness Index | 2 | 2010 | 15829 | 0.010 |
Why?
|
Health Surveys | 1 | 2008 | 4036 | 0.010 |
Why?
|
Adrenal Cortex Hormones | 1 | 2007 | 1878 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2010 | 10754 | 0.010 |
Why?
|
Disease Progression | 1 | 2014 | 13495 | 0.010 |
Why?
|
Pyrazoles | 1 | 2007 | 2008 | 0.010 |
Why?
|
Health Resources | 1 | 2002 | 934 | 0.010 |
Why?
|
Kidney Diseases | 1 | 2007 | 2090 | 0.010 |
Why?
|
Regression Analysis | 1 | 2005 | 6339 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2008 | 3451 | 0.010 |
Why?
|
Pyridines | 1 | 2007 | 2875 | 0.010 |
Why?
|
Mortality | 1 | 2004 | 2899 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2005 | 3680 | 0.010 |
Why?
|
Blood Glucose | 1 | 2006 | 6390 | 0.010 |
Why?
|
Heart Diseases | 1 | 2005 | 2778 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2008 | 14599 | 0.010 |
Why?
|
Coronary Disease | 1 | 2004 | 5911 | 0.010 |
Why?
|
Massachusetts | 1 | 2002 | 8835 | 0.010 |
Why?
|
Health Care Costs | 1 | 2002 | 3238 | 0.010 |
Why?
|
Physicians | 1 | 2005 | 4583 | 0.000 |
Why?
|